Sglt2 Inhibitor
Prophylactic CV medication appears to lower MI, death risk in diabetes without prior CVD
Residents of Denmark with diabetes and no prior CVD experienced a 61% risk reduction for MI and a 41% for death from 1996 to 2011, according to data presented at the virtual European Society of Cardiology Congress.
FDA fast tracks empagliflozin for reduced all-cause mortality, HF hospitalization risk
Top in endocrinology: Intermittent fasting, triple therapy for diabetes
Continuous glucose monitoring can help people with well-managed diabetes safely try intermittent fasting, according to experts. It was the top story in endocrinology last week.
Top in cardiology: Menopause and CVD, aspirin bleeding risk
According to a presentation at the virtual Heart in Diabetes Conference, physicians should discuss CVD risk reduction by the time a woman hits menopause.
Dapagliflozin cuts renal, CV events in CKD, regardless of diabetes status
In the DAPA-CKD trial, treatment with the SGLT2 inhibitor dapagliflozin reduced risk for worsening renal function and death due to CVD or renal disease in patients with chronic kidney disease, both with and without type 2 diabetes.
Empagliflozin lowers CV death, hospitalizations in HFrEF with or without diabetes
The SGLT2 inhibitor empagliflozin improved CV and renal outcomes in patients with HF with reduced ejection fraction, regardless of diabetes status, according to results of the EMPEROR-Reduced trial.
Triple combination therapy may be optimal for CV protection in type 2 diabetes
Triple therapy combining an SGLT2 inhibitor, a GLP-1 receptor agonist and the thiazolidinedione pioglitazone could serve as an optimal solution for cardiovascular and renal protection in type 2 diabetes, according to a speaker.
Braunwald: SGLT2 inhibitors have influenced CV care regardless of diabetes status
Two paradigm shifts have established SGLT2 inhibitors as an important drug class to treat cardiac dysfunction and HF with reduced ejection fraction in patients with and without diabetes, according to a presentation.
FDA: Amputation risk boxed warning removed from canagliflozin
‘It’s never too late’: Tailoring glucose management in advanced CKD
Glucose management remains important for adults with diabetes and advanced chronic kidney disease as a strategy to prevent or delay progression to dialysis, prevent cardiovascular events and improve quality of life, according to a speaker.